Revista da Sociedade Brasileira de Medicina Tropical · 2014
In vitro antimalarial activity of tigecycline against Plasmodium falciparum culture-adapted reference strains and clinical isolates from the Brazilian Amazon.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ribatski-Silva Daniele, Bassi Carmen Lucia, Martin Thamires Oliveira Gasquez, Alves-Junior Eduardo, Gomes Luciano Teixeira, Fontes Cor Jésus Fernandes
Аннотация
INTRODUCTION: We evaluated the in vitro antimalarial activity of tigecycline as an alternative drug for the treatment of severe malaria.
METHODS: A chloroquine-sensitive Plasmodium falciparum reference strain, a chloroquine-resistant reference strain, and three clinical isolates were tested for in vitro susceptibility to tigecycline. A histidine-rich protein in vitro assay was used to evaluate antimalarial activity.
RESULTS: The geometric-mean 50% effective concentration (EC50%) of tigecycline was 535.5 nM (confidence interval (CI): 344.3-726.8). No significant correlation was found between the EC50% of tigecycline and that of any other tested antimalarial drug.
CONCLUSIONS: Tigecycline may represent an alternative drug for the treatment of patients with severe malaria.
METHODS: A chloroquine-sensitive Plasmodium falciparum reference strain, a chloroquine-resistant reference strain, and three clinical isolates were tested for in vitro susceptibility to tigecycline. A histidine-rich protein in vitro assay was used to evaluate antimalarial activity.
RESULTS: The geometric-mean 50% effective concentration (EC50%) of tigecycline was 535.5 nM (confidence interval (CI): 344.3-726.8). No significant correlation was found between the EC50% of tigecycline and that of any other tested antimalarial drug.
CONCLUSIONS: Tigecycline may represent an alternative drug for the treatment of patients with severe malaria.